Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

Timothy Iveson, James Paul, Takayuki Yoshino et al.|Journal of Clinical Oncology|2019

Cited by 41